Reference:
1. Abdelhafez, M.M.A., et al., Intrahepatic cholestasis of pregnancy: from an obstetrician point of view. J Obstet Gynaecol, 2022: p. 1-8.
2. Bicocca, M.J., J.D. Sperling, and S.P. Chauhan, Intrahepatic cholestasis of pregnancy: Review of six national and regional guidelines. Eur J Obstet Gynecol Reprod Biol, 2018. 231: p. 180-187.
3. Glantz, A., H.U. Marschall, and L.A. Mattsson, Intrahepatic cholestasis of pregnancy: Relationships between bile acid levels and fetal complication rates. Hepatology, 2004. 40(2): p. 467-74.
4. Gao, X.X., et al., Prevalence and risk factors of intrahepatic cholestasis of pregnancy in a Chinese population. Sci Rep, 2020. 10(1): p. 16307.
5. Chappell, L.C., et al., Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet, 2019. 394(10201): p. 849-860.
6. Kumar, P. and A. Kulkarni, UDCA therapy in intrahepatic cholestasis of pregnancy? J Hepatol, 2020. 72(3): p. 586-587.
7. Lee, R.H., et al., Society for Maternal-Fetal Medicine Consult Series #53: Intrahepatic cholestasis of pregnancy: Replaces Consult #13, April 2011. Am J Obstet Gynecol, 2021. 224(2): p. B2-b9.
8. Geenes, V., et al., Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study. Hepatology, 2014. 59(4): p. 1482-91.
9. Kawakita, T., et al., Predictors of adverse neonatal outcomes in intrahepatic cholestasis of pregnancy. Am J Obstet Gynecol, 2015. 213(4): p. 570.e1-8.
10. Brites, D., et al., Correction of maternal serum bile acid profile during ursodeoxycholic acid therapy in cholestasis of pregnancy. J Hepatol, 1998. 28(1): p. 91-8.
11. Kondrackiene, J. and L. Kupcinskas, Intrahepatic cholestasis of pregnancy-current achievements and unsolved problems. World J Gastroenterol, 2008. 14(38): p. 5781-8.
12. Ozkan, S., et al., Review of a challenging clinical issue: Intrahepatic cholestasis of pregnancy. World J Gastroenterol, 2015. 21(23): p. 7134-41.
13. Wei, W. and Y.Y. Hu, Expression of hypoxia-regulated genes and glycometabolic genes in placenta from patients with intrahepatic cholestasis of pregnancy. Placenta, 2014. 35(9): p. 732-6.
14. Shan, D., R. Dong, and Y. Hu, Current understanding of autophagy in intrahepatic cholestasis of pregnancy. Placenta, 2021. 115: p. 53-59.
15. Han, X. and R.W. Gross, The foundations and development of lipidomics. J Lipid Res, 2022. 63(2): p. 100164.
16. Wang, Y., et al., Plasma lipidomics in early pregnancy and risk of gestational diabetes mellitus: a prospective nested case-control study in Chinese women. Am J Clin Nutr, 2021. 114(5): p. 1763-1773.
17. Morillon, A.C., et al., Association between phospholipid metabolism in plasma and spontaneous preterm birth: a discovery lipidomic analysis in the cork pregnancy cohort. Metabolomics, 2020. 16(2): p. 19.
18. Zhang, L., et al., Integrated Metabolomic and Lipidomic Analysis in the Placenta of Preeclampsia. Front Physiol, 2022. 13: p. 807583.
19. Li, Y., et al., Targeted metabolomics of sulfated bile acids in urine for the diagnosis and grading of intrahepatic cholestasis of pregnancy. Genes Dis, 2018. 5(4): p. 358-366.
20. Cui, Y., et al., Diagnostic and therapeutic profiles of serum bile acids in women with intrahepatic cholestasis of pregnancy-a pseudo-targeted metabolomics study. Clin Chim Acta, 2018. 483: p. 135-141.
21. Hao, Z.M., et al., Lipoprotein lipase and lipid profiles in plasma and placenta from normal pregnancies compared with patients with intrahepatic cholestasis of pregnancy. Eur J Obstet Gynecol Reprod Biol, 2016. 203: p. 279-85.
22. Fiorucci, S., et al., Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci, 2009. 30(11): p. 570-80.
23. Sun, X., et al., Untargeted lipidomics analysis in women with intrahepatic cholestasis of pregnancy: a cross-sectional study. BJOG, 2022. 129(6): p. 880-888.
24. Langfelder, P. and S. Horvath, WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics, 2008. 9: p. 559.
25. Hu, J., et al., Linc02527 promoted autophagy in Intrahepatic cholestasis of pregnancy. Cell Death Dis, 2018. 9(10): p. 979.
26. Dong, R., et al., Elevated GABRP expression is correlated to the excessive autophagy in intrahepatic cholestasis of pregnancy. Heliyon, 2023. 9(2): p. e13221.
27. Mathur, D., et al., Intrahepatic cholestasis of pregnancy: dilemma in diagnosis and management. J Matern Fetal Neonatal Med, 2022. 35(25): p. 8975-8981.
28. Dann, A.T., et al., Plasma lipid profiles of women with intrahepatic cholestasis of pregnancy. Obstet Gynecol, 2006. 107(1): p. 106-14.
29. Klionsky, D.J., et al., Autophagy in major human diseases. Embo j, 2021. 40(19): p. e108863.
30. Cao, W., et al., An overview of autophagy: Mechanism, regulation and research progress. Bull Cancer, 2021. 108(3): p. 304-322.
31. Nakashima, A., et al., Current Understanding of Autophagy in Pregnancy. Int J Mol Sci, 2019. 20(9).
32. Zhang, T., et al., Comparative proteomics analysis of placenta from pregnant women with intrahepatic cholestasis of pregnancy. PLoS One, 2013. 8(12): p. e83281.
33. Fang, D., et al., Comprehensive Analysis of Quantitative Proteomics With DIA Mass Spectrometry and ceRNA Network in Intrahepatic Cholestasis of Pregnancy. Front Cell Dev Biol, 2022. 10: p. 854425.
34. van der Veen, J.N., et al., The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease. Biochim Biophys Acta Biomembr, 2017. 1859(9 Pt B): p. 1558-1572.
35. Vance, J.E., Phosphatidylserine and phosphatidylethanolamine in mammalian cells: two metabolically related aminophospholipids. J Lipid Res, 2008. 49(7): p. 1377-87.
36. Calzada, E., O. Onguka, and S.M. Claypool, Phosphatidylethanolamine Metabolism in Health and Disease. Int Rev Cell Mol Biol, 2016. 321: p. 29-88.
37. Fu, S., et al., Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity. Nature, 2011. 473(7348): p. 528-31.
38. Runwal, G., et al., LC3-positive structures are prominent in autophagy-deficient cells. Sci Rep, 2019. 9(1): p. 10147.
39. Del Gaudio, I., et al., Sphingolipid Signature of Human Feto-Placental Vasculature in Preeclampsia. Int J Mol Sci, 2020. 21(3).
40. Wang, L.L., et al., The metabolic landscape of decidua in recurrent pregnancy loss using a global metabolomics approach. Placenta, 2021. 112: p. 45-53.
41. Chauvin, S., et al., Aberrant TGFβ Signalling Contributes to Dysregulation of Sphingolipid Metabolism in Intrauterine Growth Restriction. J Clin Endocrinol Metab, 2015. 100(7): p. E986-96.
42. Mikucka-Niczyporuk, A., et al., Role of sphingolipids in the pathogenesis of intrahepatic cholestasis. Prostaglandins Other Lipid Mediat, 2020. 147: p. 106399.